



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

28th May, 2025

Corporate Relationship Department
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400001

The Manager - Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E) Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Schedule III Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that among other items of business the Board of Directors, at their meeting held on 28th May, 2025 has, inter alia:

1. Approved the appointment of M/s. BK & Associates, Firm Registration No. S2014TL379400 as the Secretarial Auditors of the Company for a period of five consecutive years commencing from Financial Year 2025-26 to FY 2029-2030, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting.
2. Designated Mr. Dilip Manikchand Dhore as Vice President – Corporate Quality Assurance of the Company w.e.f. 1st June, 2025.
3. Designated Mr. Addagada Veerananarayana as Associate Vice President – Operations of the Company w.e.f. w.e.f. 1st June, 2025.
4. Designated Mr. Kurada Venkata Maruti Ramchander as Associate Vice President – Regulatory Affairs of the Company w.e.f. w.e.f. 1st June, 2025.
5. Designated Mr. Parupalli Sreenivasa Rao as Associate Vice President – Operations of the Company w.e.f. w.e.f. 1st June, 2025.
6. Designated Mr. Amber Roy as Associate Vice President – Distribution of the Company w.e.f. w.e.f. 1st June, 2025.

The required information in compliance with SEBI No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith.

The aforesaid information will also be available on the website of the Company at www.natcopharma.co.in

We request you to kindly take the above on record.

Thanking you,
Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary & Compliance Officer

Encl. As above



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Annexure

Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is as under:

Sl. No.	Particulars			
1.	Name	M/s. BK & Associates, Company Secretaries	Mr. Dilip Manikchand Dhore	Mr. Addagada Veerananarayana
2.	Reason for Change / Appointment	Appointment under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Secretarial Auditors	Designated as Vice President – Corporate Quality Assurance	Designated as Associate Vice President – Operations
3.	Date of appointment /reappointment/cessation (as applicable) & term of appointment/re-appointment	The Board at its meeting held on 28 th May, 2025, approved the appointment of M/s. BK & Associates, Company Secretaries, Hyderabad, Firm Registration No. S2014TL379400, Peer Review No.: 6428/2025 as Secretarial Auditors, for an audit period of five consecutive years commencing from FY2025-26 till FY2029-30, subject to approval of the shareholders at the ensuing Annual General Meeting	1 st June, 2025 & Terms of appointment are as per the Company's Policy	1 st June, 2025 & Terms of appointment are as per the Company's Policy
4.	Brief profile	BK & Associates is a Hyderabad-based Peer Reviewed Firm with over a decade of experience in providing end-to-end corporate, legal, financial, and regulatory advisory services. The firm specializes in Company Law, FEMA (FDI, OI, ECB), SEBI Laws, FCRA, M&A, CSR, CSR Impact Assessment and startup advisory. It serves a diverse clientele including corporates, non-profits, and overseas investors with practical, compliant, and value-driven solutions. The firm is led by CS Kiran Kumar Bodla [BBA, LL.M(JGLS), FCS, DARB(ICSII), PGDAM(MNLU)] and a team of professionals with strong regulatory expertise and sectoral experience.	Mr. Dilip Manikchand Dhore is a Post Graduate in Chemistry with overall experience in Quality Assurance, Quality Control and regulatory Affairs. He has been associated with the Company for past 15 years. Prior to that he was associated with Mylan India Private Limited as Senior Manager - Quality Assurance and Regulatory Affairs	Mr. Addagada Veerananarayana is competent and result oriented professional with 24 years of dynamic career in managing operations of pharmaceutical dosage forms. He has been associated with the Company for the past 5 years.
5.	Disclosure of relationship between Directors	Not Applicable	Not Applicable	Not Applicable



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Sl. No.	Particulars			
1.	Name	Mr. Kurada Venkata Maruti Ramchander	Mr. Parupalli Sreenivasa Rao	Mr. Amber Roy
2.	Reason for Change / Appointment	Designated as Associate Vice President – Regulatory Affairs	Designated as Associate Vice President – Operations	Designated as Associate Vice President – Distribution
3.	Date of appointment /reappointment/cessation (as applicable) & term of appointment/re-appointment	1 st June, 2025 & Terms of appointment are as per the Company's Policy	1 st June, 2025 & Terms of appointment are as per the Company's Policy	1 st June, 2025 & Terms of appointment are as per the Company's Policy
4.	Brief profile	Mr. Kurada Venkata Maruti Ramchander has more than 16 years pharmaceutical experience comprising 8 years in regulatory Affairs. He is well versed with regulatory requirements for dossier submissions. He has been associated with the Company for past 10 years. Prior to that he was associated with Mylan Laboratories Limited	Mr. Parupalli Sreenivasa Rao is a seasoned pharmaceutical professional with a post graduate degree in pharmacy and over 37 years of comprehensive experience in pharmaceutical formulations. Demonstrated expertise in manufacturing operations, plant administration, and regulatory compliance across diverse product lines. Proven leadership in managing large scale production units, ensuring quality, efficiency, and continuous improvement. Adept at aligning manufacturing strategies with organizational goals while fostering a culture of operational excellence and team development.	Mr. Amber Roy has extensive experience in managing supply chain, Distribution & Logistics of finished and cold chain products including sample and promotional stocks, Depot, CFA Management, Commercial, Planning, Replenishment. He has been associated with the Company for the past 9 years. Prior to that he was associated with Dr. Reddy's Labs Limited.
5.	Disclosure of relationship between Directors	Not Applicable	Not Applicable	Not Applicable